![post-1](https://s3.amazonaws.com/findit-pictures/351133/0aab0db8-e908-4151-962c-ad2724f50c08.jpg)
AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications
AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer
AIkido Pharma Inc. Announces Results of 2020 Annual Stockholder Meeting
AIkido Pharma Inc. Announces Publication of Favorable Peer Reviewed Study of Newly Licensed Antiviral Compounds
AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC
AIkido Pharma Announces Update On Its Use Of Artificial Intelligence
AIkido Pharma Inc. Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)
AIkido Pharma Announces Peer-Reviewed Publication of Positive Results from Study of Antiviral Compounds Licensed from University of Maryland, Baltimore
AIkido Pharma Sponsors Survival Study of University of Kentucky Anticancer Drug G4-1 in Exchange for Exclusive Option to License